Obstetrics & Gynecology · 3 h ago
AMH Decline Patterns Linked to Postmenopausal Cardiovascular Risk
In a SWAN cohort analysis of 1,131 women with at least three perimenopausal AMH measurements, researchers identified two patterns of decline leading to the final menstrual period. The lower-starting, slower-decline pattern was associated with a worse postmenopausal cardiovascular risk profile.
- Two AMH decline patterns were identified in 1,131 women.
- Low/slow decline was associated with worse postmenopausal cardiovascular risk profiles.
- Trajectory groups did not differ by smoking or presumptive PCOS history.
Researchers analyzed data from the Study of Women’s Health Across the Nation (SWAN), a multisite, multiethnic cohort. The analysis included 1,131 women with an observed final menstrual period and at least three anti-Müllerian hormone (AMH) measurements during perimenopause. Statistical modeling identified two AMH trajectory groups.
The low/slow group included 448 women (39.6%), with a median AMH decline of 1.2 pg/mL per month. The high/fast group included 683 women (60.4%), with a median decline of 6.7 pg/mL per month. Low/slow trajectories were associated with older age, higher baseline BMI and non-White race and ethnicity. This group also had worse postmenopausal cardiovascular risk profiles and was less likely to report frequent vasomotor symptoms after the final menstrual period. The groups did not differ by history of oligomenorrhea, presumptive polycystic ovary syndrome or smoking.
The findings describe associations in a subset of SWAN participants; they do not establish that AMH trajectories cause cardiovascular risk or show that AMH measurement should guide clinical care. The study reports modeled trajectory classes and does not provide evidence that using them improves risk assessment or outcomes.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Obstetrics & Gynecology: Anti-Müllerian Hormone Trajectories Across the Menopause Transition ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.